Clinical Trials: Regulatory Audit Findings

Sponsor Oversight Failures in GCP Training Audit Reports

Posted on digi By digi

Sponsors are ultimately accountable for ensuring that all parties involved in a clinical trial—including investigators, site staff, and CRO personnel—are adequately trained in Good Clinical Practice (GCP) and protocol-specific requirements. Regulators such as the FDA, EMA, and MHRA expect sponsors to maintain robust oversight of training activities. Failures in this area are a frequent cause of audit findings, highlighting deficiencies in governance and accountability.

Click to read the full article.

GCP Training & Compliance Audit Findings, Regulatory Audit Findings

IMP Accountability Gaps Cited in Site-Level Audit Findings

Posted on digi By digi

Investigational Medicinal Products (IMPs) form the backbone of clinical trials, and their accountability is a cornerstone of regulatory compliance. IMP accountability involves documenting the receipt, storage, dispensing, return, and destruction of trial drugs. Regulators such as the FDA, EMA, and MHRA require that investigator sites maintain complete and accurate IMP accountability records.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Sponsor Oversight Failures in Investigational Product Management

Posted on digi By digi

Sponsors are ultimately accountable for ensuring proper management of Investigational Medicinal Products (IMPs), even when tasks are delegated to CROs or investigator sites. IMP management covers receipt, storage, dispensing, reconciliation, return, and destruction. Regulatory agencies such as the FDA, EMA, and MHRA expect sponsors to maintain oversight of these activities. Failures in oversight frequently appear in audit findings, often leading to major observations that delay approvals or compromise trial data integrity.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Temperature Excursion Documentation Deficiencies in Audit Reports

Posted on digi By digi

Investigational Medicinal Products (IMPs) must be stored, transported, and handled within strictly defined temperature ranges to ensure product integrity and patient safety. Regulatory bodies including the FDA, EMA, and MHRA require comprehensive documentation of any temperature excursions, i.e., instances where IMPs are exposed to conditions outside the approved storage range.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Storage Condition Deviations Noted in IMP Audit Findings

Posted on digi By digi

Investigational Medicinal Products (IMPs) must be stored under strictly defined conditions to maintain their quality, stability, and safety. Regulatory authorities such as the FDA, EMA, and MHRA require sponsors, CROs, and investigator sites to monitor and document storage conditions meticulously. Deviations from approved ranges often result in audit findings, raising concerns about product integrity and patient safety.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Randomization and Blinding Failures Identified in Inspections

Posted on digi By digi

Randomization and blinding are critical components of clinical trial design, ensuring unbiased allocation of participants and reducing the risk of investigator or subject bias. Regulatory agencies such as the FDA, EMA, and MHRA require sponsors and investigators to maintain rigorous processes and documentation to preserve trial integrity. Failures in randomization or blinding are among the most serious regulatory audit findings because they can directly undermine the credibility of trial outcomes.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Missing IMP Destruction Certificates in Regulatory Audit Reports

Posted on digi By digi

Investigational Medicinal Products (IMPs) must be destroyed in accordance with regulatory requirements and protocol specifications once they are expired, damaged, or no longer required for a trial. Regulatory authorities such as the FDA, EMA, and MHRA expect destruction to be documented with signed certificates to demonstrate accountability. Missing IMP destruction certificates are a recurring regulatory audit finding, raising concerns about compliance, product diversion, and patient safety risks.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Labeling and Packaging Errors Highlighted in IMP Supply Chain Audits

Posted on digi By digi

Accurate labeling and compliant packaging of Investigational Medicinal Products (IMPs) are essential to ensure patient safety, maintain blinding, and meet regulatory requirements. Errors in labeling or packaging can compromise randomization, mislead investigators, or even endanger trial participants. Regulatory agencies such as the FDA, EMA, and MHRA closely scrutinize IMP supply chains, and deficiencies in labeling or packaging are among the most common audit findings.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

Comparator and Placebo Handling Gaps in Regulatory Findings

Posted on digi By digi

Comparators and placebos are essential components of controlled clinical trial designs, providing a benchmark for evaluating the safety and efficacy of investigational products. Proper handling, documentation, and accountability of comparators and placebos are critical to maintaining trial validity and regulatory compliance. Authorities such as the FDA, EMA, and MHRA routinely audit supply chain practices and often identify gaps in comparator and placebo management as significant findings.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings

IMP Recall Documentation Deficiencies Cited in Audit Reports

Posted on digi By digi

Investigational Medicinal Product (IMP) recalls may be initiated due to quality concerns, protocol changes, labeling errors, or safety issues. Regulatory agencies such as the FDA, EMA, and MHRA expect sponsors, CROs, and investigator sites to maintain complete, traceable documentation of recalls to ensure accountability and patient safety. Missing or inadequate recall documentation is a recurring audit finding, undermining trial integrity and regulatory compliance.

Click to read the full article.

Clinical Trial Supply & IMP Audit Findings, Regulatory Audit Findings